Search

Your search keyword '"Garber, Alan"' showing total 1,479 results
Start Over Author "Garber, Alan"
1,479 results on '"Garber, Alan"'

3. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary

Author

Handelsman, Yehuda, Jellinger, Paul S., Guerin, Chris K., Bloomgarden, Zachary T., Brinton, Eliot A., Budoff, Matthew J., Davidson, Michael H., Einhorn, Daniel, Fazio, Sergio, Fonseca, Vivian A., Garber, Alan J., Grunberger, George, Krauss, Ronald M., Mechanick, Jeffrey I., Rosenblit, Paul D., Smith, Donald A., and Wyne, Kathleen L.

Published
2020
Full Text
View/download PDF

4. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary

Author

Garber, Alan J., Handelsman, Yehuda, Grunberger, George, Einhorn, Daniel, Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bush, Michael A., DeFronzo, Ralph A., Garber, Jeffrey R., Garvey, W.Timothy, Hirsch, Irl B., Jellinger, Paul S., McGill, Janet B., Mechanick, Jeffrey I., Perreault, Leigh, Rosenblit, Paul D., Samson, Susan, and Umpierrez, Guillermo E.

Published
2020
Full Text
View/download PDF

5. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary

Author

Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A., Garber, Jeffrey R., Garvey, W. Timothy, Grunberger, George, Handelsman, Yehuda, Hirsch, Irl B., Jellinger, Paul S., McGill, Janet B., Mechanick, Jeffrey I., Rosenblit, Paul D., and Umpierrez, Guillermo E.

Published
2019
Full Text
View/download PDF

6. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.

Author

Kazi, Dhruv S, Garber, Alan M, Shah, Rashmee U, Dudley, R Adams, Mell, Matthew W, Rhee, Ceron, Moshkevich, Solomon, Boothroyd, Derek B, Owens, Douglas K, and Hlatky, Mark A

Subjects
Cost Effectiveness Research, Comparative Effectiveness Research, Clinical Trials and Supportive Activities, Heart Disease - Coronary Heart Disease, Cardiovascular, Heart Disease, Atherosclerosis, Clinical Research, Genetics, Good Health and Well Being, Acute Coronary Syndrome, Adenosine, Alleles, Aryl Hydrocarbon Hydroxylases, Clopidogrel, Coronary Thrombosis, Cost-Benefit Analysis, Cytochrome P-450 CYP2C19, Decision Support Techniques, Direct Service Costs, Drug Therapy, Combination, Drugs, Generic, Genotype, Hemorrhage, Humans, Percutaneous Coronary Intervention, Piperazines, Platelet Aggregation Inhibitors, Polymorphism, Genetic, Prasugrel Hydrochloride, Quality-Adjusted Life Years, Risk Factors, Thiophenes, Ticagrelor, Ticlopidine, Clinical Sciences, Public Health and Health Services
Abstract

BackgroundThe choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available.ObjectiveTo determine the most cost-effective strategy for dual antiplatelet therapy after percutaneous coronary intervention for ACS.DesignDecision-analytic model.Data sourcesPublished literature, Medicare claims, and life tables.Target populationPatients having percutaneous coronary intervention for ACS.Time horizonLifetime.PerspectiveSocietal.InterventionFive strategies were examined: generic clopidogrel, prasugrel, ticagrelor, and genotyping for polymorphisms of CYP2C19 with carriers of loss-of-function alleles receiving either ticagrelor (genotyping with ticagrelor) or prasugrel (genotyping with prasugrel) and noncarriers receiving clopidogrel.Outcome measuresDirect medical costs, quality-adjusted life years(QALYs), and incremental cost-effectiveness ratios (ICERs).Results of base-case analysisThe clopidogrel strategy produced$179 301 in costs and 9.428 QALYs. Genotyping with prasugrel was superior to prasugrel alone, with an ICER of $35 800 per QALY relative to clopidogrel. Genotyping with ticagrelor was more effective than genotyping with prasugrel ($30 200 per QALY relative to clopidogrel). Ticagrelor was the most effective strategy($52 600 per QALY relative to genotyping with ticagrelor).Results of sensitivity analysisStronger associations between genotype and thrombotic outcomes rendered ticagrelor substantially less cost-effective ($104 800 per QALY). Genotyping with prasugrel was the preferred therapy among patients who could not tolerate ticagrelor.LimitationNo randomized trials have directly compared genotyping strategies or prasugrel with ticagrelor.ConclusionGenotype-guided personalization may improve the cost-effectiveness of prasugrel and ticagrelor after percutaneous coronary intervention for ACS, but ticagrelor for all patients may bean economically reasonable alternative in some settings.

Published
2014

9. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary

Author

Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A., Garber, Jeffrey R., Garvey, W. Timothy, Grunberger, George, Handelsman, Yehuda, Hirsch, Irl B., Jellinger, Paul S., McGill, Janet B., Mechanick, Jeffrey I., Rosenblit, Paul D., and Umpierrez, Guillermo E.

Published
2018
Full Text
View/download PDF

13. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Author

Jellinger, Paul S., Handelsman, Yehuda, Rosenblit, Paul D., Bloomgarden, Zachary T., Fonseca, Vivian A., Garber, Alan J., Grunberger, George, Guerin, Chris K., Bell, David S.H., Mechanick, Jeffrey I., Pessah-Pollack, Rachel, Wyne, Kathleen, Smith, Donald, Brinton, Eliot A., Fazio, Sergio, Davidson, Michael, Davidson, Michael H., Smith, Donald A., Bush, Michael, and Zangeneh, Farhad

Published
2017
Full Text
View/download PDF

14. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 Diabetes Management Algorithm – 2017 Executive Summary

Author

Garber, Alan J., Abrahamson, Martin J., Barzilay, Joshua I., Blonde, Lawrence, Bloomgarden, Zachary T., Bush, Michael A., Dagogo-Jack, Samuel, DeFronzo, Ralph A., Einhorn, Daniel, Fonseca, Vivian A., Garber, Jeffrey R., Garvey, W. Timothy, Grunberger, George, Handelsman, Yehuda, Hirsch, Irl B., Jellinger, Paul S., McGill, Janet B., Mechanick, Jeffrey I., Rosenblit, Paul D., and Umpierrez, Guillermo E.

Published
2017
Full Text
View/download PDF

24. Following Your Heart or Your Head: Focusing on Emotions versus Information Differentially Influences the Decisions of Younger and Older Adults

Author

Mikels, Joseph A., Lockenhoff, Corinna E., Maglio, Sam J., Carstensen, Laura L., Goldstein, Mary K., and Garber, Alan

Abstract

Research on aging has indicated that whereas deliberative cognitive processes decline with age, emotional processes are relatively spared. To examine the implications of these divergent trajectories in the context of health care choices, we investigated whether instructional manipulations emphasizing a focus on feelings or details would have differential effects on decision quality among younger and older adults. We presented 60 younger and 60 older adults with health care choices that required them to hold in mind and consider multiple pieces of information. Instructional manipulations in the emotion-focus condition asked participants to focus on their emotional reactions to the options, report their feelings about the options, and then make a choice. In the information-focus condition, participants were instructed to focus on the specific attributes, report the details about the options, and then make a choice. In a control condition, no directives were given. Manipulation checks indicated that the instructions were successful in eliciting different modes of processing. Decision quality data indicate that younger adults performed better in the information-focus than in the control condition whereas older adults performed better in the emotion-focus and control conditions than in the information-focus condition. Findings support and extend extant theorizing on aging and decision making as well as suggest that interventions to improve decision-making quality should take the age of the decision maker into account. (Contains 1 footnote, 4 tables and 1 figure.)

Published
2010
Full Text
View/download PDF

28. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Author

Garber, Alan J, King, Allen B, Prato, Stefano Del, Sreenan, Seamus, Balci, Mustafa K, Muñoz-Torres, Manuel, Rosenstock, Julio, Endahl, Lars A, Francisco, Ann Marie Ocampo, and Hollander, Priscilla

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results